Drug Trial Radar · NCT07937553
Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma.
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 15, 2025
Primary completion
Aug 1, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Kidney Cancer Research BureauAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC. Lenvatinib plus everolimus (LEN+EVE) has demonstrated clinical activity in clear cell RCC (Study 205), with responses also reported in non-clear cell subtypes, including chRCC. Lenvatinib plus pembrolizumab (LEN+PEMBRO) demonstrated a high objective response rate (ORR) in KEYNOTE-B61, including in the chRCC subgroup. These findings support conducting a prospective phase 2 study specifically dedicated to this rare subtype to provide direct evidence of the efficacy and safety of these two active combinations.
Conditions
- Metastatic Chromophobe Renal Cell Carcinoma
Interventions
LenvatinibDrug
tablets
PembolizumabDrug
solution
everolimusDrug
tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: 12 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Chelyabinsk, Russia · Recruiting
V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
Krasnoyarsk, Russia · Recruiting
Orenburg Regional Cancer Center
Orenburg, Russia · Recruiting
Dr. Berezin Medical Institute
Saint Petersburg, Russia · Recruiting
SBHI Leningrad regional clinical hospital, Saint-Petersburg
Saint Petersburg, Russia · Recruiting
Saratov Regional Cancer Center
Saratov, Russia · Recruiting
Republican Clinical Oncology Dispensary
Ufa, Russia · Recruiting
Sverdlovskiy Regional Oncological Dispensary
Yekaterinburg, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.